Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees

Heidi

Heidi Ackerly, Belmont, CA US

Patent application number	Description	Published
20110112279	Compositions and Methods Relating to STOP-1 - The present invention provides novel polypeptides, antibodies, antagonists, agonists, potentiators, nucleic acid molecules, compositions and methods relating to the STOP-1 polypeptide that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides consensus sequences and specific sequences for antibodies that specifically bind to STOP-1 that are useful in the methods described herein.	05-12-2011

Heidi Boerzel, Ludwigshafen DE

Patent application number	Description	Published
20100178506	PROCESS FOR THE PRODUCTION OF MOLDINGS - Process for the production of a molding from particulate and/or fibrous substrates based on renewable raw materials and a formaldehyde-free, aqueous binder.	07-15-2010

Heidi Brurok, Trondheim NO

Patent application number	Description	Published
20100166667	MAGNETIC RESONANCE IMAGING - A method of determining the amount of intracellular manganese in the myocardium of an individual pre-administered with a manganese contrast agent, or a pharmaceutically acceptable salt thereof, comprising subjecting said individual to a MRI procedure to assess the signal intensity (SI) of images, or more preferably the longitudinal relaxation rate, R	07-01-2010

Heidi Caroline, Meadville, PA US

Patent application number	Description	Published
20080231114	System and Method for Adaptive Islanding for Stored/Distributed Energy Devices - When a fault occurs in an energy distribution network, adaptive islanding is initiated to supply energy to customers who are disconnected from the primary source of energy on the network. The customers are selectively connected to secondary energy resources that are distributed within the network. The selected customers are chosen in accordance with a profile that takes into account the amount of energy available from the distributed resources, the expected length of time to repair the fault, the recent energy demands of the customers, and levels of priority that are assigned to respective customers. These factors are monitored, and the selected customers who are connected to the distributed resources are dynamically adjusted during the time that the fault exists.	09-25-2008
20080238710	system and method for demand dispatch and load management - Provided is a system and method for monitoring utilization of a resource across an entire distribution area. The system dynamically and intelligently limits the aggregated utilization of the resource across an entire distribution area or targeted sub areas. Targeted usage thresholds at the device (individual utilization) level, as well as utility-specified business and technical rules and overrides, can be applied. Using these rules, the system continuously looks for and manages individual utilization of the resource that is available for curtailment, thus producing a larger and more efficient utilization level that is available for reduction without service impact to customers within that service area or targeted sub areas.	10-02-2008
20080249826	System and method for integrated asset protection - Provided is a system and method for monitoring in real time the status of assets of a resource distribution system and enacting a change in the resource utilization in order to protect the assets before they reach a failed state. The system may include sensors, a central control system, and a demand dispatch system. The system and method may protect individual or holistic resource distribution system assets by monitoring the operating conditions of those assets and governing the aggregated resource utilization within the governed service area.	10-09-2008

Heidi Chen, Wyckoff, NJ US

Patent application number	Description	Published
20090318504	Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods - This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist.	12-24-2009

Heidi Drummer, Victoria AU

Patent application number	Description	Published
20110014209	RECOMBINANT HCV E2 GLYCOPROTEIN - The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof.	01-20-2011

Heidi Emilia, Saxell DE

Patent application number	Description	Published
20100105562	Crystalline Form of 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)-pyr- imidinyl]-4-fluoro-N-[[methyl(1-methylethyl)amino]sulfonyl]benzamide - The present invention relates to a crystalline form of 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)-amino]sulfonyl]benzamide. The invention also relates to a process for the preparation of this crystalline form and to plant protection formulations which comprise this crystalline form of the phenyluracil.	04-29-2010

Heidi Hemmoranta, Helsinki FI

Patent application number	Description	Published
20100055678	Method of profiling a cell population - The present invention relates to a method of profiling a cell population comprising a step of detecting the presence or absence of at least two biological markers in said cell population, wherein at least one of said markers is a cell surface marker, which is a sialylated N-glycan marker with structure NeuNAcα3Gal, and at least one of said markers is a mRNA marker related to glycoproteins and/or glycosynthase proteins. The invention also relates to method for purification of cord blood cell population and to a complete cell population from cord blood purified by said method.	03-04-2010

Heidi Himmanen, Turku FI

Patent application number	Description	Published
20090067384	METHOD AND SYSTEM TO ENABLE SIMULTANEOUS RECEPTION OF PLURALITY OF SERVICES IN DVB SYSTEMS - A method comprises dividing a time frequency frame into a plurality of slots, the frame having one or more radio-frequency (RF) channels, determining a maximum slot length, and scheduling service data in symbols such that all service data symbols are within the maximum slot length of symbols corresponding to at least one common service part.	03-12-2009
20090097446	METHOD AND SYSTEM TO GUARANTEE SERVICE RECEPTION WITHIN BROADCAST SYSTEM - A system and method is provided for ensuring that time for tuning to another RF channel between two TF frames in TF slicing exists while reception with a single hopping-tuner is enabled, and reception for terminals can be guaranteed when transmitting and receiving common services. An additional time for tuning is introduced for TF-sliced services, where the time for tuning can be inserted either before of after the P	04-16-2009
20090109918	SYSTEM AND METHOD FOR IMPROVED SCHEDULING FOR TIME-FREQUENCY SLICING - A system and method for improved scheduling for time-frequency slicing. According to various embodiments, slot allocations are made so as to guarantee time for tuning between slots. When scheduling services for multiplexes covering multiple radio frequency (RF) channels, time is provided for the receiver to tune to another radio-frequency channel between at least two of the time frequency frames. This is accomplished by arranging slots so that a service carried in a slot within the tuning time before the end of a time frequency frame k is not transmitted in a slot within the tuning time after the beginning of the next time frequency frame k+1.	04-30-2009
20090196217	Signalling the Presence of Extension Frames - Aspects of the invention are directed to signalling extension frames in a telecommunication system. Extension-frame-signalling data may signal whether one or more extension parts are present in one or more gaps in time between data frames, when the one or more extension parts occur, and one or more durations for the one or more extension parts. The one or more extension parts may occur on the same radio frequencies as the data frames. The extension-frame-signalling data may signal when the one or more extension parts occur by signalling after which of one or more data frames in a super frame the extension parts occur. The one or more durations for the extension parts may be expressed in units of time.	08-06-2009

Heidi Himmannen, Turku FI

Patent application number	Description	Published
20090164873	SYSTEM AND METHOD FOR IMPROVING SIGNALING CHANNEL ROBUSTNESS - A system and method for improving signaling channel robustness. Additional error correction is provided for (L	06-25-2009

Heidi Kahelin, Espoo FI

Patent application number	Description	Published
20110065940	Method for the production of fat - The present invention relates to a method for the production of fat with a principal application as transportation biofuel or a component or raw material therefor. According to the method, cell masses, cell suspensions and/or liquid phases formed in the production of single cell oil, and/or biomass-containing side streams or microorganism cell masses for another purpose and/or originating from other sources, are contacted with a fat-production capable microorganism and the organism is allowed to produce fat. The resulting fat is recovered or the microorganism mass is passed to a single-cell oil production process. By means of the invention, the organic matter present in the cell mass and side streams of single-cell oil can be re-utilized for the production of the single-cell oil, thereby improving a total fat yield, as well as reducing an organic load of the side streams.	03-17-2011

Heidi Kaulfuerst-Soboll, Ascheberg DE

Patent application number	Description	Published
20110047657	METHOD FOR GENERATING HYPOALLERGENIC GLYCOPROTEINS IN MUTATED OR TRANSGENIC PLANTS OR PLANT CELLS, AND MUTATED OR TRANSGENIC PLANTS AND PLANT CELLS FOR GENERATING HYPOALLERGENIC GLYCOPROTEINS - Method for providing a hypoallergenic glycoprotein includes growing at least one of a mutated plant, a part of the mutated plant, plant cells produced from the mutated plant, a transgenic plant, a part of the transgenic plant and plant cells produced from the transgenic plant wherein an activity of an enzyme Golgi α-mannosidase II has been eliminated or decreased so as to obtain a grown material. The hypoallergenic glycoprotein is isolated from the grown material.	02-24-2011

Heidi Knechtli, Rheineck CH

Patent application number	Description	Published
20090206750	Method for the Production of an Electroluminescence Apparatus and an Electroluminescence Apparatus Produced According to Said Method - An electroluminescence apparatus (	08-20-2009
20110043104	Electroluminescence (EL) Device and Method for the Production Thereof - An electroluminescence (EL) device includes a planar electroluminescence (EL) layer, on the rear of which two segment electrodes are disposed insulated next to and nested inside each other in an electrode plane and can be connected to an alternating current source, and on the front of which at least one transparent front electrode, particularly in the form of one or more graphical elements, are disposed in an insulated manner. In such an EL device, luminosity that is practically independent of the shape of the counter-electrodes and uniform across the surface is provided, and a formation of the graphical elements by simple cutting out or stamping out is enabled, in that the nesting of the segment electrodes is configured such that the segment electrodes are alternately disposed in two independent directions of the electrode plane.	02-24-2011

Heidi Landert, Bourrignon CH

Patent application number	Description	Published
20110098485	BIDENTATE SECONDARY PHOSPHINE OXIDE CHIRAL LIGANDS FOR USE IN ASYMMETRIC ADDITION REACTIONS - Compounds of the formula I, in the form of mixtures comprising predominantly one enantiomer or in the form of pure enantiomers, secondary phosphine-Q-P*(═O)HR	04-28-2011
20110118482	BIDENTATE CHIRAL LIGANDS FOR USE IN CATALYTIC ASYMMETRIC ADDITION REACTIONS - Compounds of the formula (I), in the form of mixtures comprising predominantly one diastereomer or in the form of pure diastereomers, Z	05-19-2011

Heidi Mediaas, Stavanger NO

Patent application number	Description	Published
20100292349	PROCESS - A process for the preparation of at least one ARN acid or salt thereof comprising: (I) allowing at least one ARN acid salt to form during the production of crude oil in the presence of water; (II) removing at least 5 wt % of the formed at least one ARN acid salt, e.g. from the oil water interface; and optionally (III) converting said salt into an acid.	11-18-2010

Heidi Misteli, Basel CH

Patent application number	Description	Published
20100239535	METHOD FOR ISOLATING HOMOGENEOUS POPULATIONS OF TRANSDUCED PROGENITORS STABLY EXPRESSING SPECIFIC LEVELS OF A TRANSGENE - The invention is directed to a method for producing precursor cells expressing a target gene, for example VEGF, at desired levels comprising stably transducing precursor cells with the target gene linked to a cell-surface marker gene, for example truncated CD8/CD8	09-23-2010

Heidi Moosdorf, Ursensollen DE

Patent application number	Description	Published
20110014987	RIDING FLOOR ASSEMBLY - A riding floor assembly has a support layer laid on a subfloor. The support layer, or ground preparation layer, is formed of ground preparation elements that are substantially formed of plates and are arranged next to one another. A footing layer covers the upper side of the ground preparation layer. A plurality of tufts of bristles are provided on that side of the ground preparation layer facing toward the footing layer. The tufts of bristles have a length selected such that the bristles do not project out of the footing layer.	01-20-2011

Heidi Osterholm, Porvoo FI

Patent application number	Description	Published
20090270245	CATALYTIC MATERIALS AND METHOD FOR THE PREPARATION THEREOF - The invention is related to catalytic materials and particularly to mesoporous molecular sieves embedded with a zeolite, which are thermally stable at a temperature of at least 900° C., and to a method for the preparation of the catalytic materials. Said catalytic materials are suitable for applications in the field of hydrocarbon processing.	10-29-2009

Heidi Pickreign, Harvard, MA US

Patent application number	Description	Published
20090259890	Method & apparatus for hardware fault management - A hardware health evaluation module is associated with a hardware module or device and employs a linked list of error records to continually evaluate the state of the hardware module to determine whether or not it is currently operating with or without errors. In the event that the health evaluation module determines that the hardware module is not operating in an error free manner, it detects and stores, for a specified period of time, an indication of the error and associates this detected error or errors with one or more of the error records. The error records are designed to provide assistance in diagnosing the cause of a hardware error.	10-15-2009

Heidi Rolfes, Pretoria ZA

Patent application number	Description	Published
20080213858	Stabilization of Enzymes - A process for producing enzymes structures includes providing an emulsion of droplets of a first liquid phase dispersed in a second liquid phase. The one liquid phase is a hydrophilic phase, while the other liquid phase is a hydrophobic phase which is immiscible with the hydrophilic phase. Enzyme molecules are located at or within interfacial boundaries of the droplets and the second liquid phase. The enzyme molecules of the respective droplets are cross-linked so that individual enzyme structures, which are stable and in which the enzymes are immobilized with a majority of active sites of the enzymes being orientated either internally or externally, are formed from individual droplets.	09-04-2008

Heidi Rommelaere, Gent BE

Patent application number	Description	Published
20110053865	AMINO ACID SEQUENCES DIRECTED AGAINST HETERODIMERIC CYTOKINES AND/OR THEIR RECEPTORS AND POLYPEPTIDES COMPRISING THE SAME - The present invention relates to amino acid sequences that are directed against (at defined herein) heterodimeric cytokines and/or their receptors, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consists of one or more such amino acid sequences ( also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively). The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides (also referred to herein as “nucleic acids of the invention” or “nucleotides sequences of the invention”); to methods for preparing such amino acid sequences and polypeptides; to hose cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that complete such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes mentioned herein.	03-03-2011

Heidi Schmitt, Aumuehle DE

Patent application number	Description	Published
20090074942	GRANULAR LECITHINS, GRANULAR LYSOLECITHINS, PROCESS FOR THEIR PRODUCTION AND COMPOSITIONS CONTAINING THEM - There is disclosed a granular lecithin and the use in many applications, such as nutraceutical compositions. Also disclosed is a process for producing granular lecithins and compositions containing lecithins.	03-19-2009

Heidi Schreuder-Gibson, Holliston, MA US

Patent application number	Description	Published
20110236689	Polymeric Composition for the Neutralization of Noxious Agents - The present application is directed to a novel composition which acts as a barrier to noxious agents while adding self-detoxifying catalytic treatments to neutralize the noxious and harmful warfare agents when applied for example on a fabric, or other solid support.	09-29-2011

Heidi Spiegal, Hamden, CT US

Patent application number	Description	Published
20100249523	SURGICAL ACCESS PORT AND ASSOCIATED INTRODUCER MECHANISM - A surgical portal assembly includes a portal member adapted for positioning within a tissue tract and defining a longitudinal axis with leading and trailing ends. The portal member includes at least one longitudinal port for passage of an object. The portal member comprises a compressible material adapted to transition between a first expanded condition to facilitate securing of the portal within the tissue tract and in substantial sealed relation with tissue surfaces defining the tissue tract, and a second compressed condition to facilitate at least partial insertion of the portal within the tissue tract. The portal assembly also includes an elongated member extending through the at least one longitudinal port and mechanically couplable to the portal member adjacent the leading end thereof. The elongated member is adapted to move through the at least one longitudinal port in a trailing direction to exert a compressive force at least adjacent the leading end to cause the portal member to transition toward the compressed condition.	09-30-2010

Heidi Straatmann, Julich DE

Patent application number	Description	Published
20080247515	Rotor - The invention concerns a rotor combining the advantages of a single-piece wheel, which, when it is operating, only exhibits a slight and constant variation in shape (expansion shift) in the guiding region of its path, with those of a rimmed rotor with spokes, enabling, by virtue of its light weight, the bearings to be easily arranged. Further, because of its tendency to exhibit a tensile stress higher than a bending load, the rotor provides for a wide selection of rotor materials. The rotor has at least one segment arranged on the hub, enclosing at least a closed recess. A preferred embodiment concerns a rotor comprising at least three rotor segments uniformly distributed, said segments having each two recesses, such that the regions of materials surrounding them are in the form of three spokes arranged substantially parallel. The inventive rotor is particularly suitable for receiving graphite crystals, in the form or a vibrating disc for a back-scattering spectrometer.	10-09-2008

Heidi Trusheim, Muenchhausen DE

Patent application number	Description	Published
20100010199	MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS - Currently, the steps performed prior to release of influenza strains to vaccine manufacturers involve passaging influenza virus through eggs. The invention aims to provide procedures useful in manufacturing influenza vaccines, in which the use of eggs is reduced, and preferably is avoided altogether. For instance, rather than use chicken eggs for influenza vaccine isolation, MDCK cells (Madin Darby canine kidney cells) may be used e.g. growing in suspension, growing in a serum-free medium, growing in a protein-free medium, being non-tumorigenic, grown in the absence of an overlay medium, etc.	01-14-2010